https://www.biopharma-reporter.com/Article/2022/12/21/biontech-starts-phase-1-trial-for-herpes-virus-vaccine
0
0
12/21/22 at 9:31pm
Organization
BioPharma-Reporter.com
Author
biopharma-reporter.com
39 words
0
Comments
BioNTech has dosed the first participant in a Phase 1 trial for BNT163, a herpes simplex virus (HSV) vaccine candidate for HSV-2 and potentially HSV-1.
You are the first to view
Create an account
or login to join the discussion